Taysha Gene Therapies, Inc. $TSHA Shares Sold by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. reduced its stake in Taysha Gene Therapies by 62.9%, owning approximately 0.17% of the company post-sale, valued at $499,000.
• Insider Sukumar Nagendran sold 200,000 shares for $646,000, resulting in a 16.58% decrease in their holdings.
• Several analysts have set new price targets for the stock, with Chardan Capital raising it to $10.00 and an average target of $8.29 according to MarketBeat.com.

Goldman Sachs Group Inc. cut its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 62.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 359,007 shares of the company's stock after selling 608,137 shares during the period. Goldman Sachs Group Inc. owned approximately 0.17% of Taysha Gene Therapies worth $499,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Ameriprise Financial Inc. acquired a new stake in Taysha Gene Therapies during the fourth quarter valued at approximately $40,000. BNP Paribas Financial Markets acquired a new stake in Taysha Gene Therapies during the fourth quarter valued at approximately $41,000. ProShare Advisors LLC raised its holdings in shares of Taysha Gene Therapies by 32.3% during the fourth quarter. ProShare Advisors LLC now owns 59,076 shares of the company's stock valued at $102,000 after acquiring an additional 14,418 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Taysha Gene Therapies during the first quarter valued at approximately $117,000. Finally, MetLife Investment Management LLC raised its holdings in shares of Taysha Gene Therapies by 71.0% during the first quarter. MetLife Investment Management LLC now owns 107,711 shares of the company's stock valued at $150,000 after acquiring an additional 44,721 shares during the period. 77.70% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total transaction of $646,000.00. Following the transaction, the insider owned 1,006,439 shares in the company, valued at $3,250,797.97. This represents a 16.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.78% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

TSHA has been the topic of a number of recent analyst reports. Chardan Capital boosted their price target on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. Needham & Company LLC restated a "buy" rating and set a $8.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, July 1st. Wells Fargo & Company boosted their price target on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the company an "overweight" rating in a report on Wednesday, August 13th. Citigroup restated an "outperform" rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. Finally, JMP Securities boosted their price target on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the company a "market outperform" rating in a report on Thursday, May 29th. Eight analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $8.29.

Taysha Gene Therapies Stock Down 2.9%

Taysha Gene Therapies stock opened at $3.06 on Friday. The firm has a market cap of $834.77 million, a PE ratio of -9.00 and a beta of 0.98. The company has a debt-to-equity ratio of 0.17, a quick ratio of 12.48 and a current ratio of 12.48. The firm's 50 day moving average price is $2.89 and its two-hundred day moving average price is $2.39. Taysha Gene Therapies, Inc. has a twelve month low of $1.05 and a twelve month high of $3.40.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The company had revenue of $1.99 million during the quarter, compared to analyst estimates of $1.61 million. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. On average, research analysts predict that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.